Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.63 |
| ▸ | RXRA | P19793 | 2/20 | 0.61 |
| ▸ | RXRB | P28702 | 2/20 | 0.61 |
| ▸ | RXRG | P48443 | 2/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15447763 | 0.90 | FFAR1 (0.61) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL13524569 | 0.90 | FFAR1 (0.56) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL19843544 | 0.89 | FFAR1 (0.59) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL13524596 | 0.85 | RXRA (0.65) | FFAR1RXRARXRBRXRG | |
| SCHEMBL765928 | 0.83 | KEAP1 (0.55) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL1510137 | 0.80 | FFAR1 (0.69) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL25146340 | 0.79 | FFAR4 (0.59) | FFAR1FFAR4AKR1B1LIPG | |
| SCHEMBL879572 | 0.79 | ALDH1A1 (0.59) | FFAR1FFAR4 | |
| SCHEMBL18563482 | 0.79 | FFAR1 (0.67) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL8618654 | 0.79 | FFAR1 (1.00) | FFAR1RXRARXRBRXRGFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | FFAR1 2938/4885RXRA 3455/4885RXRB 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.